相关实验视频

Updated: Jun 25, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

以EGFR外基因组20插入突变治疗晚期非小细胞肺癌的现状和突破

Meng Hu¹, Congying Zhong¹, Jiabing Wang¹

¹Department of Oncology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.

Frontiers in immunology

|May 22, 2024

概括

新的向疗法对非小细胞肺癌 (NSCLC) 患者具有罕见的EGFR外因子20插入突变的新有前途. 这些新兴的治疗方法在传统疗法失败的地方提供了希望,解决了精准医学中至关重要的未满足需求.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
精准医学是一门精准的医学.

背景情况:

非小细胞肺癌 (NSCLC) 治疗已通过向疗法和免疫疗法取得进展,特别是对于常见的EGFR突变.
EGFR外因子20插入 (ex20ins) 突变带来了独特的结构挑战,使它们对传统的氨酸激酶抑制剂 (TKI) 无反应.
对于EGFR ex20ins突变的NSCLC患者有效的治疗方法存在重大未满足的需求.

研究的目的:

审查针对EGFR ex20ins突变的NSCLC的新兴疗法.
突出正在进行的临床试验和该领域最近的研究进展.
讨论与为这种患者群体开发新型治疗方法相关的挑战.

主要方法:

文献综述,重点关注最近针对NSCLC的向治疗和免疫治疗方面的进展.
对新型EGFR-TKI和其他新兴治疗方式的临床试验数据的分析.
讨论EGFR ex20ins突变的结构特征及其对治疗反应的影响.

主要成果:

第一代和第二代向药物对EGFR ex20ins突变的疗效有限.
第三代和新型向药物,包括新型EGFR-TKI,显示出有前途的疗效.
化疗提供相对有利的结果,而免疫疗法的有效性仍在研究中,因为数据有限.

结论:

新型向疗法,特别是新型EGFR-TKI,在治疗EGFR ex20ins突变的NSCLC方面取得了重大进展.
尽管取得了进展,但优化治疗策略和克服抵抗机制仍然存在挑战.
持续的研究和临床试验至关重要,以充分实现新兴疗法对这一患者群体的潜力.

关键词:

在EGFR的exon 20插入 (ex20ins) 突变中.免疫疗法免疫疗法这是一种新型药物EGFR-TKI.非小细胞肺癌的肺癌.有针对性的治疗.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...